Literature DB >> 24045451

Measured versus estimated total liver volume to preoperatively assess the adequacy of the future liver remnant: which method should we use?

Dario Ribero1, Marco Amisano, Francesca Bertuzzo, Serena Langella, Roberto Lo Tesoriere, Alessandro Ferrero, Daniele Regge, Lorenzo Capussotti.   

Abstract

OBJECTIVES: To determine which method of liver volumetry is more accurate in predicting a safe resection.
BACKGROUND: Before major or extended hepatectomy, assessment of the future liver remnant (FLR) is crucial to reduce the risk of postoperative hepatic insufficiency. The FLR volume is usually expressed as the ratio of FLR to nontumorous total liver volume (TLV), which can be measured directly by computed tomography (mTLV) or estimated (eTLV) on the basis of correlation existing with the body surface area. To date, these 2 methods have never been compared.
METHODS: All consecutive, noncirrhotic patients who underwent resection of 3 or more liver segments between April 2000 and April 2012 and for whom (i) preoperative computed tomographic scans and (ii) body surface area were available entered the study. The mTLV (calculated as TLV - tumor volume) was compared with the eTLV (calculated as -794.41 + 1267.28 × body surface area) using volumetric data (cm) and clinical outcome measures (specifically, hepatic insufficiency and 90-day mortality). Definition of hepatic insufficiency was peak postoperative serum total bilirubin level of more than 7 mg/dL or, in jaundiced patients, an increasing bilirubin level on day 5 or thereafter.
RESULTS: Two-hundred forty-three patients who had undergone major (n = 135) or extended (n = 108) hepatectomies met the inclusion criteria. Twenty-eight patients (11.5%) developed hepatic insufficiency, whereas 7 patients (2.9%) died postoperatively. Compared with the eTLV, the mTLV underestimated the liver volume in 60.1% of the patients (P < 0.01). Forty-seven and 73 patients had an inadequate FLR based on mTLV and eTLV, respectively. Portal vein occlusion (PVO) was used in 44 patients. In patients (n = 162) in whom both methods did not evidence the need for PVO, postoperative hepatic insufficiency and mortality were 4.9% and 0.6%, respectively. Conversely, in patients (n = 27) in whom the eTLV but not the mTLV evidenced the need for PVO, and thus PVO was not performed, hepatic insufficiency (22.2%; P = 0.001) and mortality (3.7%; P = ns) were higher.
CONCLUSIONS: The use of eTLV identifies a subset of patients (∼11%) in whom liver volumetry with the mTLV underestimates the risk of hepatic insufficiency.

Entities:  

Mesh:

Year:  2013        PMID: 24045451     DOI: 10.1097/SLA.0000000000000213

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

1.  Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure.

Authors:  Universe Leung; Amber L Simpson; Raphael L C Araujo; Mithat Gönen; Conor McAuliffe; Michael I Miga; E Patricia Parada; Peter J Allen; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; Yuman Fong; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2014-06-25       Impact factor: 6.113

2.  Liver function following extended hepatectomy can be accurately predicted using remnant liver volume to body weight ratio.

Authors:  Stéphanie Truant; Emmanuel Boleslawski; Géraldine Sergent; Emmanuelle Leteurtre; Alain Duhamel; Mohamed Hebbar; François-René Pruvot
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

3.  Liver volumetry: Is imaging reliable? Personal experience and review of the literature.

Authors:  Mirko D'Onofrio; Riccardo De Robertis; Emanuele Demozzi; Stefano Crosara; Stefano Canestrini; Roberto Pozzi Mucelli
Journal:  World J Radiol       Date:  2014-04-28

4.  Intraoperative simulation of remnant liver function during anatomic liver resection with indocyanine green clearance (LiMON) measurements.

Authors:  Michael N Thomas; Ernst Weninger; Martin Angele; Florian Bösch; Sebastian Pratschke; Joachim Andrassy; Markus Rentsch; Manfred Stangl; Werner Hartwig; Jens Werner; Markus Guba
Journal:  HPB (Oxford)       Date:  2015-01-08       Impact factor: 3.647

5.  Re "Comparison of techniques for volumetric analysis of the future liver remnant: implications for major hepatic resections".

Authors:  Kristoffer Watten Brudvik; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2016-03-22       Impact factor: 3.647

6.  Comparison of techniques for volumetric analysis of the future liver remnant: implications for major hepatic resections.

Authors:  Guillaume Martel; Kasia P Cieslak; Ruiyao Huang; Krijn P van Lienden; Jimme K Wiggers; Assia Belblidia; Michel Dagenais; Réal Lapointe; Thomas M van Gulik; Franck Vandenbroucke-Menu
Journal:  HPB (Oxford)       Date:  2015-09-16       Impact factor: 3.647

7.  Volume-assisted estimation of liver function based on Gd-EOB-DTPA-enhanced MR relaxometry.

Authors:  Michael Haimerl; Mona Schlabeck; Niklas Verloh; Florian Zeman; Claudia Fellner; Dominik Nickel; Ana Paula Barreiros; Martin Loss; Christian Stroszczynski; Philipp Wiggermann
Journal:  Eur Radiol       Date:  2015-07-18       Impact factor: 5.315

8.  Diagnostic accuracy of 3D imaging combined with intra-operative ultrasound in the prediction of post-hepatectomy liver failure.

Authors:  Tianchong Wu; Wenhao Huang; Baochun He; Yuehua Guo; Gongzhe Peng; Mingyue Li; Shiyun Bao
Journal:  J Gastrointest Oncol       Date:  2022-06

9.  Preoperative Cholangitis and Future Liver Remnant Volume Determine the Risk of Liver Failure in Patients Undergoing Resection for Hilar Cholangiocarcinoma.

Authors:  Dario Ribero; Giuseppe Zimmitti; Thomas A Aloia; Junichi Shindoh; Forchino Fabio; Marco Amisano; Guillaume Passot; Alessandro Ferrero; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2016-02-13       Impact factor: 6.113

Review 10.  Issues to be considered to address the future liver remnant prior to major hepatectomy.

Authors:  Yoji Kishi; Jean-Nicolas Vauthey
Journal:  Surg Today       Date:  2020-09-07       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.